Transient Immune Suppression of Inapparent Carrier Ponies Inoculated with Attenuated Equine Infectious Anemia Virus Infectious Clone.

JIANG Cheng-gang,MA Jian,LIN Yue-zhi,ZHAO Li-ping,LV Xiao-ling,HUA Yu-ping,LIU Di,ZHOU Jian-hua
DOI: https://doi.org/10.3969/j.issn.1008-0589.2010.11.01
2010-01-01
Abstract:Equine infectious anemia virus (EIAV) vaccine is the first lentiviral vaccine with a successful application, but itsmechanism on inducing protective immunity remains unclear. Our previous studies found that the gene encoding transmembraneprotein (gp45) of EIAV vaccine strain EIAVFDDV12 had a high-frequent G2230A mutation to create a stop coding, resulting in atruncation of 154 amino acid residues at the C-terminus. To explore the biological meaning of the gp45 truncation, a molecularclone EIAVFDDVTM-36 with truncated gp45 was constructed using EIAVFDDVTM-45 as the backbone. Eight ponies were randomly groupedand inoculated with either EIAVFDDVTM-36 or EIAVFDDVTM-45 and transient immune suppression was induced by daily injection ofdexamethasone for 10 days. The results showed that treatment of dexamethasone did not appear to alter the plasma viral loads andserum neutralizing antibody activities in EIAVFDDVTM-36-inoculated ponies, however it significantly increased plasma viral loads inthree of four EIAVFDDVTM-45-inoculated ponies after the transient immune suppression were observed. Furthermore, the treatment ofdexamethasone significantly enhanced the serum neutralizing activity of the EIAVFDDVTM-45 group of ponies (p0.05). It appeared thatspecific immune pressure had no effect on EIAVFDDVTM-36 replication in vivo, rather limited the production EIAVFDDVTM-45, implicatingan elevated safety of EIAVFDDVTM-36 as an EIAV vaccine. On the other hand, the increased plasma viral loads and a higherneutralization antibody activity in EIAVFDDVTM-45-inoculated ponies indicated that the protection efficacy and the safety of EIAVattenuated vaccines may be negatively correlated. Therefore, it was important to carefully balance these two criteria of lentiviralvaccines.
What problem does this paper attempt to address?